p53, the most commonly mutated gene in cancer cells, directs cell cycle arr
est or induces programmed cell death (apoptosis) in response to stress. It
has been demonstrated that p53 activity is up-regulated in part by posttran
slational acetylation. In agreement with these observations, here we show t
hat mammalian histone deacetylase (HDAC)-1, -2, and -3 are all capable of d
ownregulating p53 function. Down-regulation of p53 activity by HDACs is HDA
C dosage-dependent, requires the deacetylase activity of HDACs, and depends
on the region of p53 that is acetylated by p300/CREB-binding protein (CBP)
. These results suggest that interactions of p53 and HDACs likely result in
p53 deacetylation, thereby reducing its transcriptional activity. In suppo
rt of this idea, GST pull-down and immunoprecipitation assays show that p53
interacts with HDAC1 both in vitro and in vivo. Furthermore, a pre-acetyla
ted p53 peptide was significantly deacetylated by immunoprecipitated wild t
ype HDAC1 but not deacetylase mutant. Also, coexpression of HDAC1 greatly r
educed the in vivo acetylation level of p53. Finally, we report that the ac
tivation potential of p53 on the BAX promoter, a natural p53-responsive sys
tem, is reduced in the presence of HDACs. Taken together; our findings indi
cate that deacetylation of p53 by histone deacetylases is likely to be part
of the mechanisms that control the physiological activity of p53.